Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Depreciation & Amortization (CF) (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $357000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 10.53% year-over-year to $357000.0; the TTM value through Oct 2025 reached $1.5 million, down 15.62%, while the annual FY2025 figure was $1.6 million, 12.16% down from the prior year.
  • Depreciation & Amortization (CF) reached $357000.0 in Q4 2025 per CSBR's latest filing, roughly flat from $358000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $583000.0 in Q2 2023 and bottomed at $297000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $434750.0, with a median of $422000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 87.46% in 2022, then dropped 21.61% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $346000.0 in 2021, then skyrocketed by 61.85% to $560000.0 in 2022, then dropped by 13.57% to $484000.0 in 2023, then decreased by 17.56% to $399000.0 in 2024, then dropped by 10.53% to $357000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $357000.0 in Q4 2025, $358000.0 in Q3 2025, and $394000.0 in Q2 2025.